Arax Advisory Partners’s Spyre Therapeutics SYRE Stock Holding History

Arax Advisory Partners’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Buy	169 +151	+839%	+$11K	﹤0.01%	4134
2026 Q1	$908	Buy	+18	New	+$679	﹤0.01%	3323
2025 Q4	–	Sell	-121	Closed	-$2.03K	–	4515
2025 Q3	$2.03K	Buy	+121	New	+$1.97K	﹤0.01%	3114

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Arax Advisory Partners's SYRE Position: Q2 2026 in Review

Arax Advisory Partners increased its Spyre Therapeutics (SYRE) stake by 839% in Q2 2026, buying an estimated $11K and bringing the position to 169 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4134.

Arax Advisory Partners first reported a position in SYRE in Q3 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Arax Advisory Partners held 169 shares of Spyre Therapeutics worth $15K as of Q2 2026.
Arax Advisory Partners bought 151 Spyre Therapeutics shares in Q2 2026, an estimated $11K.
Spyre Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4134 holding.
Arax Advisory Partners first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.